Teledoc To Go Public
The Dallas-based telemedicine pioneer said in a securities filing Thursday that it plans to raise up to $136.9 million in its initial public offering. Meanwhile, Charlotte-based Premier introduces a reimbursement tracking tool and Heartland Health Monitor explores both the promise and perplexities of a new stroke prevention tool.
The Wall Street Journal:
Teladoc Outlines IPO Terms
Teladoc Inc., an early player in the field of telemedicine, said in a securities filing Thursday that it plans to raise up to $136.9 million in its initial public offering. The company had confidentially filed IPO paperwork in April. According to a regulatory filing, the company plans to sell 7 million shares for $15 to $17 a share. Underwriters have the option to purchase up to 1.05 million additional shares, Teladoc said. (Beilfuss, 6/18)
The Charlotte Observer:
Premier Introduces New Reimbursement Tracking Technology
Charlotte-based Premier Inc. has introduced a new technology that it says uses clinical outcomes to predict the financial impact of federal payment programs on health care systems. Premier Quality Cycle Management analyzes which facilities, clinicians and clinical outcomes impact reimbursements, as well as how similar health care systems perform. According to a statement from the company Thursday, the new technology also offers Premier’s advisory services on how the system can improve. (Peralta, 6/18)
Heartland Health Monitor:
New Stroke Prevention Device Illustrates Promise, Perplexity Of Health Breakthroughs
Charles Welty began seriously worrying about his heart health at the gym. The 78-year-old retired civil engineer said that while running on a treadmill, he saw something startling on the machine’s heart monitor. “My pulse rate was undetectable,” Welty said during a recent interview in his Lenexa home. A visit to his doctor revealed that his worries were not unfounded. His doctor’s diagnosis: atrial fibrillation, a condition in which the heart’s chambers beat out of sync with each other. Fortunately for Welty, earlier this year the Food and Drug Administration approved a new device to help atrial fibrillation patients. (Smith, 6/18)
